Inspira Technologies Gains New Patent for Innovative Blood Oxygenation System
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, NASDAQ: IINNW) has reached an important milestone by obtaining a second U.S. patent for its advanced blood oxygenation delivery system, known as the VORTX™. This groundbreaking technology plays a vital role in the functionality of the INSPIRA™ ART device.
Revolutionary Technology for ICU Patients
The VORTX™ system is notable for its ability to oxygenate blood without the need for traditional fiber membranes. This innovative approach aims to support the roughly 20 million intensive care unit patients experiencing respiratory failure each year, many of whom rely on mechanical ventilators in a competitive $19 billion market.
Enhancements Offered by the VORTX™ System
The newly granted patent adds to a total of 32 claims associated with the INSPIRA™ ART device, showcasing the transformative impact this technology can have in modern healthcare. The VORTX™ system is engineered to reduce blood cell damage, offering a revolutionary approach to blood oxygenation that avoids many harmful side effects linked to turbulent blood flow through fiber materials. By eliminating fiber membranes, the VORTX™ seeks to prevent issues like hemolysis and activated immune responses.
Comments from Company Leadership
Dagi Ben-Noon, the CEO of Inspira Technologies, expressed excitement about the new patent approval, stating that it represents another significant step toward enhancing blood oxygenation technologies. He highlighted the company’s commitment to ensuring patient comfort and safety while providing an innovative alternative to conventional ventilators.
Significance and Market Opportunities
The INSPIRA™ ART technology is set to transform the experience for patients facing respiratory issues. Unlike mechanical ventilators, the INSPIRA™ ART promotes stable oxygen levels, which allows many patients to stay conscious during their treatment. This represents a shift in how respiratory care is provided in intensive care environments.
About Inspira Technologies
Inspira Technologies stands out as a pioneering force in the medical technology sector, focusing on respiratory treatments. Their leading technology, the INSPIRA™ ART, features advanced blood monitoring systems that enhance patient safety and minimize the need for invasive procedures typically associated with mechanical ventilation.
Certifications and Future Innovations
The company’s INSPIRA™ ART100 system has secured FDA clearance for cardiopulmonary bypass procedures and holds the AMAR certification for both ECMO and cardiopulmonary bypass uses in select markets. Additionally, Inspira is working on developing other innovative devices, such as the INSPIRA™ Cardi-ART portable module and the HYLA™ blood sensor, aimed at improving patient care further.
Frequently Asked Questions
What is the primary focus of Inspira Technologies?
Inspira Technologies is dedicated to creating advanced medical technologies that enhance respiratory treatment methods, especially for ICU patients.
What innovations does the VORTX™ system introduce?
The VORTX™ system provides a method for oxygenating blood without using fiber membranes, aiming to reduce blood cell damage and improve outcomes for patients.
How many U.S. patents does Inspira Technologies have for its device?
Inspira Technologies has secured a total of 32 unique claims related to its central INSPIRA™ ART technology through the latest patent approvals.
What impact does Inspira's technology have on ICU patient treatment?
The INSPIRA™ ART allows ICU patients to maintain stable oxygen levels while remaining awake, which may decrease the need for invasive mechanical ventilation.
What certifications has the INSPIRA™ ART system achieved?
The INSPIRA™ ART100 system has received FDA 510(k) clearance and the AMAR certification for its use in cardiopulmonary bypass procedures.
